Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.ijcard.2021.05.012
Title: | Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention | Authors: | Bhatt, Deepak L. Kaski, Juan Carlos Delaney, Sean Alasnag, Mirvat Andreotti, Felicita Angiolillo, Dominick J. Ferro, Albert Gorog, Diana A. Lorenzatti, Alberto J. Mamas, Mamas McNeil, John Nicolau, Jose C. Steg, Philippe Gabriel Tamargo, Juan Tan, Doreen Valgimigli, Marco |
Keywords: | Antiplatelet therapy Crowdsourcing High bleeding risk Non-ST segment elevation acute coronary syndrome P2Y12 receptor inhibitors Percutaneous coronary intervention |
Issue Date: | 1-Aug-2021 | Publisher: | Elsevier Ireland Ltd | Citation: | Bhatt, Deepak L., Kaski, Juan Carlos, Delaney, Sean, Alasnag, Mirvat, Andreotti, Felicita, Angiolillo, Dominick J., Ferro, Albert, Gorog, Diana A., Lorenzatti, Alberto J., Mamas, Mamas, McNeil, John, Nicolau, Jose C., Steg, Philippe Gabriel, Tamargo, Juan, Tan, Doreen, Valgimigli, Marco (2021-08-01). Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. International Journal of Cardiology 337 : 1-8. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijcard.2021.05.012 | Rights: | Attribution-NonCommercial-NoDerivatives 4.0 International | Abstract: | Aims: Choosing an antiplatelet strategy in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) at high bleeding risk (HBR), undergoing post-percutaneous coronary intervention (PCI), is complex. We used a unique open-source approach (crowdsourcing) to document if practices varied across a small, global cross-section of antiplatelet prescribers in the post-PCI setting. Methods and results: Five-hundred and fifty-nine professionals from 70 countries (the ‘crowd’) completed questionnaires containing single- or multi-option and free form questions regarding antiplatelet clinical practice in post-PCI NSTE-ACS patients at HBR. A threshold of 75% defined ‘agreement’. There was strong agreement favouring monotherapy with either aspirin or a P2Y12 inhibitor following initial DAPT, within the first year (94%). No agreement was reached on the optimal duration of DAPT or choice of monotherapy: responses were in equipoise for shorter (?3 months, 51%) or longer (?6 months, 46%) duration, and monotherapy choice (45% aspirin; 53% P2Y12 inhibitor). Most respondents stated use of guideline-directed tools to assess risk, although clinical judgement was preferred by 32% for assessing bleeding risk and by 46% for thrombotic risk. Conclusion: The crowdsourcing methodology showed potential as a tool to assess current practice and variation on a global scale and to achieve a broad demographic representation. These preliminary results indicate a high degree of variation with respect to duration of DAPT, monotherapy drug of choice following DAPT and how thrombotic and bleeding risk are assessed. Further investigations should concentrate on interrogating practice variation between key demographic groups. © 2021 The Author(s) | Source Title: | International Journal of Cardiology | URI: | https://scholarbank.nus.edu.sg/handle/10635/232599 | ISSN: | 0167-5273 | DOI: | 10.1016/j.ijcard.2021.05.012 | Rights: | Attribution-NonCommercial-NoDerivatives 4.0 International |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1016_j_ijcard_2021_05_012.pdf | 657.06 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License